Esperion Therapeutics Inc (LTS:0IIM)
$ 2.135 0.1668 (8.47%) Market Cap: 424.83 Mil Enterprise Value: 504.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Esperion Therapeutics Inc Announces Study 1002-058 Phase 2 Top-Line Results Conference Call Transcript

Aug 29, 2019 / 12:00PM GMT
Release Date Price: $36.3
Operator

Good day, ladies and gentlemen, and welcome to the Esperion Study 058 Top-Line Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Alex Schwartz, Senior Director of Investor Relations. Sir, you may begin.

Alexander Duke Schwartz
Esperion Therapeutics, Inc. - Senior Director of IR

Thank you. Good morning, ladies and gentlemen, and welcome. I'm Alex Schwartz, Head of Investor Relations here at Esperion. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. With us today from Esperion are Tim Mayleben, President and Chief Executive Officer; Bill Sasiela, Senior Vice President, Clinical Development; and Mark Glickman, Chief Commercial Officer.

I'd like to remind callers that information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot